CureVac Announces a Possible Vaccine Against Covid-19

CureVac Announces a Possible Vaccine Against Covid-19 The chief executive of the German biotechnology firm CureVac, said on Sunday that the company does not rule out the possibility of launching its prospective vaccine against Covid 19 in mid-2021, in a speedy approval for the vaccine amid an international competition. The CEO of German biotechnology firm CureVac, was quoted as saying on Sunday that the company does not rule out the speedy approval of a possible vaccine against Covid-19. Obtaining speedy approval suggests the company is pushing for an earlier release date although CEO Franz-Werner Haas did not give any details on how likely this was. CureVac, backed by Microsoft founder and billionaire Bill Gates, listed on the Nasdaq stock market on Friday, raising $213 million. The results of the recently started clinical trials of the company's prospective vaccine are to be published in autumn, Haas said, reiterating that at the moment approval was expected in the first half of next year. The company is working to develop a vaccine that carries a specific genetic code called RNA. Researchers hope they can compel a patient's own body to create proteins that can play an important role in combating disease. "We see a deeper and broader understanding in the United States that the mRNA technology we use has the potential to quickly develop an effective and efficient vaccine," Haas said.   You might also be interested in:

EUR/USD: Converging COVID-19 trends to dampen bullish sentiment